Grant: Collaborative Health Research Projects
University of Toronto
$215,800.00
Advanced Bioreactors for Evaluation and Systematic Optimization of Decellularization and Recellularization of the Lung and Trachea
FY 2019-20
Summary
Diseases affecting the airways are an important clinical problem and for the majority ofpatients with end-stage disease, transplantation of lung and/or trachea has become the onlylife-saving option. Ideally we need access to off-the-shelf replacement grafts reducing thedependency on donor organs, wait-time and risk of death. In the lung, organ regeneration isachieved by using biohybrid devices with partially synthetic or natural scaffolds. The approachis to utilize advanced bioreactors operating under optimized physiological conditions torepopulate with new cells, scaffolds in which the resident cells have been removed, and usefor functional replacement of damaged tissue. While transplantation of regenerated wholelungs is a far-off goal, we exploit the simpler system of the trachea with which we haveextensive expertise while addressing key issues that will set the foundation for future clinicalapplication of whole lung grafts. At the end of the funding period, we expect to begin clinicaltranslation of a functional tracheal biograft used to address small airway and larger trachealdefects, respectively. The optimized tracheal bioreactors developed can result in commercialproducts via licensing to already existing lung biotech companies or through companycreation ventures with focus on enhanced organ-specific bioreactors. In addition, thedevelopment of a computational model of fluid flow using a computerized geometrical modelsof vascular (and airway) networks will allow in silico experimental programs to explorestrategies for targeted cell delivery. Models developed here have the potential for significantimpact in lung tissue engineering, and can be applied to research groups focused on otherorgans. Completion of this work will set in motion a therapeutic strategy with the potential tosave lives and vastly improve the quality of life of Canadians suffering from end-stage lungdisease.
Program
Collaborative Health Research Projects
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
523396-2018
Name nom
Amon, Cristina
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2018
Award amount
215800
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
2100
Research subject group en
Mechanical engineering
Research subject group fr
Génie mécanique
Research subject en
Mechanical engineering
Research subject fr
Génie mécanique
Installment
inst:2 - 3
Partie
2
Nb partie
3
Application title
Advanced Bioreactors for Evaluation and Systematic Optimization of Decellularization and Recellularization of the Lung and Trachea
Keyword
NSERC
Application summary
Diseases affecting the airways are an important clinical problem and for the majority ofpatients with end-stage disease, transplantation of lung and/or trachea has become the onlylife-saving option. Ideally we need access to off-the-shelf replacement grafts reducing thedependency on donor organs, wait-time and risk of death. In the lung, organ regeneration isachieved by using biohybrid devices with partially synthetic or natural scaffolds. The approachis to utilize advanced bioreactors operating under optimized physiological conditions torepopulate with new cells, scaffolds in which the resident cells have been removed, and usefor functional replacement of damaged tissue. While transplantation of regenerated wholelungs is a far-off goal, we exploit the simpler system of the trachea with which we haveextensive expertise while addressing key issues that will set the foundation for future clinicalapplication of whole lung grafts. At the end of the funding period, we expect to begin clinicaltranslation of a functional tracheal biograft used to address small airway and larger trachealdefects, respectively. The optimized tracheal bioreactors developed can result in commercialproducts via licensing to already existing lung biotech companies or through companycreation ventures with focus on enhanced organ-specific bioreactors. In addition, thedevelopment of a computational model of fluid flow using a computerized geometrical modelsof vascular (and airway) networks will allow in silico experimental programs to explorestrategies for targeted cell delivery. Models developed here have the potential for significantimpact in lung tissue engineering, and can be applied to research groups focused on otherorgans. Completion of this work will set in motion a therapeutic strategy with the potential tosave lives and vastly improve the quality of life of Canadians suffering from end-stage lungdisease.